09:00-17.00 EST | 07.00 – 14.00 PST

8.55 | 5.55 Chair’s Opening Remarks

COVID-19 Impact on Decentralized Clinical Trials

9.00 | 6.00 How to Continue Running Trials in Lockdown Using Decentralized Trials

  • Amir Lahav Healthcare Intelligence and Digital Transformation Consultant, Mitsubishi Tanabe Pharma America

Synopsis

  • How decentralized trials can get you back up and running and ensure continuity
  • Why the pandemic offers a chance to re-evaluate clinical research strategy to allow adaptation
  • Investing in innovation now to drive widespread adoption of DCTs

9.30 | 6.30 Panel Discussion – DCT Lessons Learned from Lockdown

  • Craig Lipset Founder Clinical, Innovation Partners
  • Jennifer Wulff Director, Global Product Development, Pfizer
  • Amir Lahav Healthcare Intelligence and Digital Transformation Consultant, Mitsubishi Tanabe Pharma America
  • Esther Middleditch International Clinical Program Leader, Roche

Synopsis

  • Discussing how the industry coped during lockdown and the benefits of shifting to incorporate
    decentralized trials

Study – Model Matching: Spotlight on Hybrid Trials

10.15 | 7.15 Virtual Speed Networking Break & Morning Coffee

Synopsis

Grab a quick cup of tea or coffee from the comfort of your own kitchen and jump straight into your opportunity to connect with new contacts from active companies in the field and exchange digital business cards. Network and form lasting connections through this exclusive virtual speed networking!

11.15 | 8.15 Personalization and the Future of the Decentralized Experience for Sites and Participants

Synopsis

  • How to commit to DCTs and decrease the reliance conventional trials
  • Examples of how DCTs have shone during the pandemic, highlighting their advantages
  • If decentralized trials are to stay, what can the industry do better?

Laying the Groundwork for Decentralized Clinical Trials

11.45 | 8.45 The Current State of Decentralized Trials

Synopsis

  • How far has the industry come, and where does it need to go to drive a successful future for decentralized trials?
  • What are the factors holding decentralized trials back, and how do we overcome them?
  • Evaluating the uptake of decentralized trials during the lockdown

11.45 | 8.45 20 years of Trials with Clinical Sites – Lessons and Issues

  • Steven Cummings Executive Director, S.F. Coordinating Center Prof. of Medicine, Epidemiology & Biostatistics, Sutter Health and UCSF

Synopsis

  • Lessons from several trials of supplements and drugs
  • Why such trials fail

 

13.45 | 10.45 Case Study: What is DEEP (Digital Endpoints Ecosystem & Protocols) and how will it help digital measures?

  • Kai Langel Director, Clinical Innovation, Janssen

Synopsis

  • Introduction to the cross-industry movement, DEEP
  • What are the goals for DEEP?
  • How DEEP will accelerate the maturity and adoption of the ecosystem around in terms of digital measures

14.15 | 11.15 Panel Discussion – Setting up Your Decentralized Trial for Success & Avoiding Crucial Mistakes

  • Steven Cummings Executive Director, S.F. Coordinating Center Prof. of Medicine, Epidemiology & Biostatistics, Sutter Health and UCSF
  • Richard Erwin Sr Director of Operations, Addario Lung Cancer Medical Institute

Synopsis

  • Discussing how to lay the groundwork when pushing forward with decentralized trials
  • Potential pitfalls to avoid and building on previous decentralized trials

15.00 | 12.00 Afternoon Networking Break

Incorporating Patient-Centric Design to Improve DCT Success

15.30 | 12.30 Fireside Chat – Discussing the Patient Experience of Decentralized Trials

Synopsis

What are the biggest downsides to decentralized trials, patient engagement at protocol design stage and what strategies can we use to improve patient engagement?

16.00 | 13.00 Case Study – Using Patient-Centric Digital Tools in Decentralized Trials to Transform Clinical Research

  • Jimmy Bechtel Director of Innovation & Engagement, Society for Clinical Research Sites

Synopsis

  • How digital health tools can boost enrolment and patient engagement throughout a trial
  • Reviewing the benefits digital tools bring to patient recruitment in decentralized clinical trials
  • How digital biomarkers are changing patient care

16.30 | 13.30 Chair’s Closing Remarks

16.35 | 13.35 End of Day 1